Mizuho Has Lowered Expectations for Lantheus (NASDAQ:LNTH) Stock Price

Lantheus (NASDAQ:LNTH) had its target price lowered by Mizuho from $120.00 to $115.00 in a report issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the medical equipment provider’s stock. Mizuho’s target price points to a potential upside of 15.44% from the company’s previous close.

Several other research firms have also recently weighed in on LNTH. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a research note on Thursday, May 7th. Truist Financial upped their price objective on Lantheus from $115.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, July 16th. Wall Street Zen lowered Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. B. Riley Financial reissued a “buy” rating on shares of Lantheus in a research note on Wednesday. Finally, Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Friday, May 8th. Eight equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Lantheus currently has a consensus rating of “Moderate Buy” and an average target price of $109.71.

Lantheus Trading Down 2.9%

Shares of LNTH stock traded down $3.02 on Wednesday, hitting $99.62. 415,803 shares of the stock traded hands, compared to its average volume of 947,285. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.64 and a current ratio of 2.83. Lantheus has a twelve month low of $47.25 and a twelve month high of $111.86. The firm’s 50-day moving average price is $103.85 and its two-hundred day moving average price is $86.19. The stock has a market capitalization of $6.49 billion, a PE ratio of 24.01 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.25 by $0.21. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. The firm had revenue of $377.33 million during the quarter, compared to analysts’ expectations of $354.48 million. During the same period last year, the business earned $1.53 earnings per share. Lantheus’s revenue was up 1.2% compared to the same quarter last year. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. As a group, analysts anticipate that Lantheus will post 4.5 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in LNTH. Versor Investments LP purchased a new stake in Lantheus during the 4th quarter worth about $519,000. M&T Bank Corp acquired a new stake in shares of Lantheus in the fourth quarter valued at approximately $539,000. Epoch Investment Partners Inc. boosted its stake in Lantheus by 59.4% during the 1st quarter. Epoch Investment Partners Inc. now owns 649,751 shares of the medical equipment provider’s stock worth $49,284,000 after purchasing an additional 242,222 shares during the period. Bleakley Financial Group LLC purchased a new position in shares of Lantheus during the fourth quarter worth about $771,000. Finally, Healthcare of Ontario Pension Plan Trust Fund lifted its holdings in shares of Lantheus by 686.1% during the first quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 598,857 shares of the medical equipment provider’s stock worth $45,423,000 after purchasing an additional 522,678 shares during the period. Hedge funds and other institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.